Accurate identification of HLA-B*15:02 allele by two-dimensional polymerase chain reaction

被引:2
|
作者
Zhu, Xueting [1 ]
Yu, Yang [1 ]
Zhang, Jun [1 ]
Zhan, Yuxia [1 ]
Luo, Guanghua [1 ]
Zheng, Lu [1 ]
机构
[1] Soochow Univ, Clin Med Res Ctr, Affiliated Hosp 3, Changzhou, Peoples R China
关键词
2D-PCR; HLA-B*15:02; Genotyping; STEVENS-JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; HLA CLASS-I; CUTANEOUS ADVERSE-REACTIONS; DRUG-REACTIONS; RISK-FACTOR; CARBAMAZEPINE; ASSOCIATION; HAN; POPULATION;
D O I
10.1016/j.cca.2023.117654
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: HLA-B*15:02 is highly associated with carbamazepine-induced SJS/TEN; however, there is no rapid and accurate detecting method. Here, we present a method to distinguish HLA-B*15:02 from 16 highly homologous HLA-B*15 alleles.Methods: The high-throughput two-dimensional polymerase chain reaction (2D-PCR) technology was employed to identify HLA-B*15:02 in two-tube reaction. And, 2D-PCR accuracy was verified by PCR-sequence based typing (PCR-SBT).Results: HLA-B*15:02 heterozygotes were identified by 14 melting valleys in the first tube reaction and none in the second, or by 13 melting valleys in the first tube reaction and one in the second. HLA-B*15:02 homozygote was identified by 13 melting valleys in the first tube reaction and none in the second. Three (0.16%) HLA-B*15:02 homozygotes and 84 (4.59%) HLA-B*15:02 heterozygotes were detected in 1830 samples of clinical general population without detecting 16 highly homologous alleles to HLA-B*15:02. The kappa test showed 100% coincidence between the 2D-PCR and PCR-SBT.Conclusions: 2D-PCR in two-tube reaction method for identifying HLA-B*15:02 was successfully established. Identification of HLA-B*15:02 is necessary prior to taking CBZ based on HLA-B*15:02 allele frequency.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Update on HLA-B*15:02 allele associated with adverse drug reactions
    Zhu, Xueting
    Luo, Guanghua
    Zheng, Lu
    PHARMACOGENOMICS, 2024, 25 (02) : 97 - 111
  • [2] A nested sequence-specific primer-polymerase chain reaction for the detection of HLA-B*15:02
    Virakul, S.
    Kupatawintu, P.
    Nakkuntod, J.
    Kangwanshiratada, O.
    Vilaivan, T.
    Hirankarn, N.
    TISSUE ANTIGENS, 2012, 79 (04): : 295 - 301
  • [3] External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy
    Lin, Guigao
    Zhang, Kuo
    Han, Yanxi
    Xie, Jiehong
    Li, Jinming
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (02)
  • [4] A study of HLA-B*15:02 in a Sri Lankan population: Implications for pharmacogenomic testing
    Gunathilake, K. M. D.
    Wettasinghe, K. T.
    Dissanayake, V. H. W.
    HUMAN IMMUNOLOGY, 2016, 77 (05) : 429 - 431
  • [5] Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy
    Gu, Yaron
    Shih, Sophy T. F.
    Geevasinga, Nimeshan
    Chan, Linda
    Frew, John W.
    Sebaratnam, Deshan F.
    JAMA DERMATOLOGY, 2024, 160 (06) : 631 - 640
  • [6] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    Chang, C-C
    Ng, C-C
    Too, C-L
    Choon, S-E
    Lees, C-K
    Chung, W-H
    Hussein, S. H.
    Lim, K-S
    Murad, S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 170 - 173
  • [7] A study of HLA-B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS']JS/TEN
    Ou, G. J.
    Wang, J.
    Ji, X.
    Yu, H.
    Jiang, L.
    Li, L.
    Chen, Q.
    Su, P. C.
    Liu, Z.
    HLA, 2017, 89 (04) : 225 - 229
  • [8] A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions
    Nguyen, D. V.
    Vidal, C.
    Chi, H. C.
    Do, N. T. Q.
    Fulton, R.
    Li, J.
    Fernando, S. L.
    HLA, 2017, 90 (06) : 335 - 342
  • [9] HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children
    Amstutz, U.
    Ross, C. J. D.
    Castro-Pastrana, L. I.
    Rieder, M. J.
    Shear, N. H.
    Hayden, M. R.
    Carleton, B. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 142 - 149
  • [10] HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese
    Wong, Christina S. M.
    Yap, Desmond Y. H.
    Ip, Patrick
    Wong, Wilfred H. S.
    Chua, Gilbert T.
    Yeung, Chi-Keung
    Chan, Henry H. L.
    Kwok, Janette S. Y.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (02) : 184 - 190